Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Subtyping of intraductal papillary mucinous neoplasms - pitfalls of MUC1 immunohistochemistry

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{3b60ef3eed3a45e8ad53509f4d5ba44f,
title = "Subtyping of intraductal papillary mucinous neoplasms - pitfalls of MUC1 immunohistochemistry",
abstract = "Intraductal papillary mucinous neoplasms (IPMNs) are precursor lesions of pancreatic ductal adenocarcinoma (PDAC). Current edition of WHO Classification of Tumors of the Digestive System recognizes four different subtypes (gastric, intestinal, pancreatobiliary, and oncocytic) and recommends analysis of mucin expression (MUC1, MUC2, MUC5AC, MUC6) as well as evaluation of architectural and cell differentiation patterns for correct classification. However, there is no consensus on MUC1 expression of IPMN-lesions in the literature. Current recommendations are based on studies where antibodies against the core MUC1 protein or sialylated MUC1 (tumor associated MUC1), not the fully glycosylated MUC1 were used. We have recently reported that MUC1 is strongly expressed in both gastric and intestinal types IPMN specimens from the cystic wall, obtained by endoscopic ultrasound guided microbiopsy procedure. We have used a commercial MUC1 antibody, validated and recommended for diagnostic use, which recognizes fully glycosylated MUC1. Based on the above, we propose a revision of the WHO Classification, specifying that antibodies against tumor associated MUC1 should be used for IPMN subtyping.",
keywords = "Gastrointestinal pathology, IPMN subtyping, MUC1, pancreas cancer, pathology of tumors, prognostic markers",
author = "Pia Klausen and Bojan Kovacevic and Anders Toxvaerd and Evangelos Kalaitzakis and Karstensen, {John G{\'a}sdal} and Rift, {Charlotte Vestrup} and Hansen, {Carsten Palnaes} and Jan Storkholm and Peter Vilmann and Hasselby, {Jane Preuss}",
note = "{\circledC} 2018 APMIS. Published by John Wiley & Sons Ltd.",
year = "2019",
month = "1",
doi = "10.1111/apm.12900",
language = "English",
volume = "127",
pages = "27--32",
journal = "APMIS - Journal of Pathology, Microbiology and Immunology",
issn = "0903-4641",
publisher = "Wiley Online",
number = "1",

}

RIS

TY - JOUR

T1 - Subtyping of intraductal papillary mucinous neoplasms - pitfalls of MUC1 immunohistochemistry

AU - Klausen, Pia

AU - Kovacevic, Bojan

AU - Toxvaerd, Anders

AU - Kalaitzakis, Evangelos

AU - Karstensen, John Gásdal

AU - Rift, Charlotte Vestrup

AU - Hansen, Carsten Palnaes

AU - Storkholm, Jan

AU - Vilmann, Peter

AU - Hasselby, Jane Preuss

N1 - © 2018 APMIS. Published by John Wiley & Sons Ltd.

PY - 2019/1

Y1 - 2019/1

N2 - Intraductal papillary mucinous neoplasms (IPMNs) are precursor lesions of pancreatic ductal adenocarcinoma (PDAC). Current edition of WHO Classification of Tumors of the Digestive System recognizes four different subtypes (gastric, intestinal, pancreatobiliary, and oncocytic) and recommends analysis of mucin expression (MUC1, MUC2, MUC5AC, MUC6) as well as evaluation of architectural and cell differentiation patterns for correct classification. However, there is no consensus on MUC1 expression of IPMN-lesions in the literature. Current recommendations are based on studies where antibodies against the core MUC1 protein or sialylated MUC1 (tumor associated MUC1), not the fully glycosylated MUC1 were used. We have recently reported that MUC1 is strongly expressed in both gastric and intestinal types IPMN specimens from the cystic wall, obtained by endoscopic ultrasound guided microbiopsy procedure. We have used a commercial MUC1 antibody, validated and recommended for diagnostic use, which recognizes fully glycosylated MUC1. Based on the above, we propose a revision of the WHO Classification, specifying that antibodies against tumor associated MUC1 should be used for IPMN subtyping.

AB - Intraductal papillary mucinous neoplasms (IPMNs) are precursor lesions of pancreatic ductal adenocarcinoma (PDAC). Current edition of WHO Classification of Tumors of the Digestive System recognizes four different subtypes (gastric, intestinal, pancreatobiliary, and oncocytic) and recommends analysis of mucin expression (MUC1, MUC2, MUC5AC, MUC6) as well as evaluation of architectural and cell differentiation patterns for correct classification. However, there is no consensus on MUC1 expression of IPMN-lesions in the literature. Current recommendations are based on studies where antibodies against the core MUC1 protein or sialylated MUC1 (tumor associated MUC1), not the fully glycosylated MUC1 were used. We have recently reported that MUC1 is strongly expressed in both gastric and intestinal types IPMN specimens from the cystic wall, obtained by endoscopic ultrasound guided microbiopsy procedure. We have used a commercial MUC1 antibody, validated and recommended for diagnostic use, which recognizes fully glycosylated MUC1. Based on the above, we propose a revision of the WHO Classification, specifying that antibodies against tumor associated MUC1 should be used for IPMN subtyping.

KW - Gastrointestinal pathology

KW - IPMN subtyping

KW - MUC1

KW - pancreas cancer

KW - pathology of tumors

KW - prognostic markers

UR - http://www.scopus.com/inward/record.url?scp=85058739582&partnerID=8YFLogxK

U2 - 10.1111/apm.12900

DO - 10.1111/apm.12900

M3 - Journal article

VL - 127

SP - 27

EP - 32

JO - APMIS - Journal of Pathology, Microbiology and Immunology

JF - APMIS - Journal of Pathology, Microbiology and Immunology

SN - 0903-4641

IS - 1

ER -

ID: 55881671